Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 1Phase 2/3 1Phase 2 1

Status

Recruiting 5Completed 1

Sponsor Class

OTHER 3INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 2Gastrointestinal 2Breast 1

Conditions

Neoplasms 6Breast Neoplasms 5Prostatic Neoplasms 4Hematologic Neoplasms 4Colorectal Neoplasms 4Melanoma 3Lung Neoplasms 3Pancreatic Neoplasms 2Malignant Solid Neoplasm 2Leukemia, Myeloid, Acute 2Hematopoietic and Lymphatic System Neoplasm 2Head and Neck Neoplasms 2COVID-19 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spondylitis, Ankylosing 1Speech 1Seroma 1Rectal Neoplasms 1Psoriasis 1Progressive Metastatic Castrate Resistant Prostate Cancer 1Postoperative Complications 1Peritoneal Neoplasms 1Parotid Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

pembrolizumab 16Bevacizumab 12Carboplatin 10Nivolumab 8Pemetrexed 7Temozolomide 6Standard of Care 6Exercise 6Cetuximab 6durvalumab 5atezolizumab 5Prednisone 5Cyclophosphamide 5abemaciclib 4Paclitaxel 4Doxorubicin 4Dexamethasone 4Cisplatin 4Blood Specimen Collection 4temsirolimus 3enzalutamide 3dostarlimab 3daratumumab 3cabozantinib 3Rituximab 3Oxaliplatin 3Metformin 3Leucovorin 3Lenalidomide 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Neoplasms × Standard of Care × 30 days × Clear all
NCT07005102 2026-06-05

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

AbbVie

Phase 2/3 Recruiting
854 enrolled
Tumor-Agnostic

Neoplasms

NCT07023289 2026-06-02

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

AbbVie

Phase 2 Recruiting
140 enrolled
Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT07324577 2026-05-22

RELAX

Wake Forest University Health Sciences

Phase NA Recruiting
54 enrolled
Tumor-Agnostic

Neoplasms

NCT07602504 2026-05-22

China Metastatic Liver Cancer Clinical Registry Cohort Database

Anhui Provincial Hospital

Recruiting
2,000 enrolled
Gastrointestinal

Liver Diseases, Liver Neoplasms, Neoplasms, Colorectal Neoplasms

NCT04515810 2026-05-18

Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning

Fred Hutchinson Cancer Center

Phase NA Recruiting
400 enrolled

Death, Neoplasms

NCT07590505 2026-05-15

ULTIMO

Cancer Research Antwerp

Phase 3 Completed
132 enrolled
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡